Tocqueville Asset Management L.P. purchased a new position in shares of AveXis, Inc. (NASDAQ:AVXS) during the second quarter, according to its most recent disclosure with the SEC. The fund purchased 6,720 shares of the company’s stock, valued at approximately $552,000.

Several other hedge funds have also recently made changes to their positions in AVXS. Nationwide Fund Advisors raised its stake in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock worth $262,000 after buying an additional 284 shares during the last quarter. American International Group Inc. raised its stake in shares of AveXis by 26.7% in the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after buying an additional 742 shares during the last quarter. Swiss National Bank raised its stake in shares of AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after buying an additional 800 shares during the last quarter. Seven Bridges Advisors LLC raised its stake in shares of AveXis by 49.4% in the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock worth $210,000 after buying an additional 846 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of AveXis by 0.5% in the second quarter. Jennison Associates LLC now owns 184,668 shares of the company’s stock worth $15,172,000 after buying an additional 882 shares during the last quarter. Hedge funds and other institutional investors own 94.71% of the company’s stock.

AveXis, Inc. (NASDAQ AVXS) opened at 91.11 on Wednesday. AveXis, Inc. has a 52-week low of $32.31 and a 52-week high of $99.45. The company has a 50 day moving average price of $89.48 and a 200 day moving average price of $76.66. The firm’s market capitalization is $2.91 billion.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same quarter in the previous year, the company posted ($0.68) EPS. On average, equities analysts forecast that AveXis, Inc. will post ($5.85) EPS for the current fiscal year.

WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/tocqueville-asset-management-l-p-invests-552000-in-avexis-inc-avxs.html.

A number of analysts recently issued reports on the company. Chardan Capital set a $103.00 price target on AveXis and gave the company a “buy” rating in a report on Sunday, June 18th. Sanford C. Bernstein began coverage on AveXis in a report on Thursday, July 27th. They set an “outperform” rating and a $108.00 target price for the company. Instinet began coverage on AveXis in a report on Tuesday. They set a “reduce” rating and a $52.00 target price for the company. Evercore ISI began coverage on AveXis in a report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price for the company. Finally, BMO Capital Markets restated a “buy” rating and set a $123.00 target price on shares of AveXis in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $95.57.

In related news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $81.88, for a total value of $145,746.40. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at approximately $145,746.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 5,340 shares of company stock worth $434,872. 18.60% of the stock is currently owned by insiders.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.